[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638327":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":31,"responsibleParty":47,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Sahlgrenska University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective cohort subjected to EUS-RFA",null,"All patientens enrolled prospectively from 2025 and onwards subjected to EUS-RFA as treatemtn for pancreatic insulinoma",[13],"Procedure: EUS-RFA",{"label":15,"type":10,"description":16,"interventionNames":10},"Control group","All patients subjected to surgery due to insulinoma during 2018-2024 acting as a historic control group",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","EUS-RFA","Treatment of insulinoma by EUS-RFA",[9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Per Hedenström, Associate Professor","CONTACT","+46 31 3421000","per.hedenstrom@vgregion.se",{"name":30,"role":26,"phone":27,"phoneExt":10,"email":10},"Riadh Sadik, Associate Professor",[32],{"facility":33,"status":34,"city":35,"state":10,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Sahlgrenska Univeristy Hospital","RECRUITING","Gothenburg","Sweden","SE",{"type":39,"coordinates":40},"Point",[41,42],11.96679,57.70716,{"lat":42,"lon":41},[45,46],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":30,"role":26,"phone":27,"phoneExt":10,"email":10},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Per Hedenström","Senior Consultant","100638327","safety-and-efficacy-of-eus-rfa-in-pancreatic-insulinoma-100638327",false,"NCT07585032","Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma","EUSRFAINSU","Inclusion Criteria:\n\n* Insulinoma verified by pathology (often from EUS-FNB-sampling)\n\nExclusion Criteria:\n\n* Patients unwilling to participate\n* Patients unable to understand and obtain written informed conscent\n* Severe comorbidity","ALL","15 Years","80 Years",{"count":62,"type":63},20,"ESTIMATED","OBSERVATIONAL","Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.\n\nIn the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.",[67],"Insulinoma; Pancreas",[69,70,71],"endosonography","insulinoma","radiofrequency ablation","2026-05-08",{"date":74,"type":75},"2026-05-13","ACTUAL",{"date":77,"type":75},"2025-03-31",{"date":79,"type":63},"2029-06",{"name":5,"class":6},1]